Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.55 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.52 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.52 |
| ▸ | GPR183 | P32249 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1025449 | 0.96 | HDAC6 (0.53) | HDAC6HDAC8HDAC3HDAC1PRMT5 | |
| SCHEMBL3281265 | 0.84 | MYC (0.54) | PRMT5WDR77GPR183MAPK14 | |
| SCHEMBL17960573 | 0.83 | CREBBP (0.52) | HDAC6HDAC8HDAC3HDAC1PRMT5 | |
| SCHEMBL1262957 | 0.79 | HDAC6 (0.64) | HDAC6HDAC8HDAC3HDAC1MAPK14 | |
| SCHEMBL1081871 | 0.79 | CHRM2 (0.42) | HDAC6PRMT5WDR77 | |
| SCHEMBL1991906 | 0.79 | HDAC6 (0.67) | HDAC6HDAC8HDAC3HDAC1 | |
| SCHEMBL4150881 | 0.78 | MAPK14 (0.60) | PRMT5WDR77GPR183MAPK14 | |
| SCHEMBL722609 | 0.78 | MAPK14 (0.53) | HDAC6HDAC8HDAC3HDAC1MAPK14 | |
| SCHEMBL1080738 | 0.77 | HDAC6 (0.67) | HDAC6HDAC8HDAC3HDAC1PRMT5 | |
| SCHEMBL1081769 | 0.75 | CHRM2 (0.42) | PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575193-B2 | N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds | 4SC AG (DE) | 2013-11-05 | — | — | US | claimed |
| US-20110201643-A1 | NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS | 4SC AG (DE) | 2011-08-18 | — | — | US | claimed |
| EP-2100879-A1 | Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds | 4SC AG (DE) | 2009-09-16 | — | — | EP | claimed |
| US-8575193-B2 | N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds | 4SC AG (DE) | 2013-11-05 | — | — | US | disclosed |
| US-20110201643-A1 | NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS | 4SC AG (DE) | 2011-08-18 | — | — | US | disclosed |
| EP-2100879-A1 | Novel N-substituted tetrahydroisoquinoline/isoindoline hydroxamic acid compounds | 4SC AG (DE) | 2009-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201643-A1 | NOVEL N-SUBSTITUTED TETRAHYDROISOQUINOLINE/ISOINDOLINE HYDROXAMIC ACID COMPOUNDS | HDAC1, HDAC3, HDAC4 | HDAC6 7/4885HDAC8 10/4885HDAC3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.